Page last updated: 2024-10-30

metformin and Fatty Liver

metformin has been researched along with Fatty Liver in 166 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research Excerpts

ExcerptRelevanceReference
"Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD."9.17Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. ( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013)
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3."9.15Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011)
"The presence of fatty liver per ultrasound and liver-associated enzymes were measured in a select cohort of youth with both obesity and insulin resistance, and the effect of metformin on these parameters evaluated."9.14Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. ( Ehlers, LB; Love-Osborne, K; Nadeau, KJ; Zeitler, PS, 2009)
"No significant differences between treatment with metformin or placebo were observed for changes in liver steatosis, assessed either histologically or by CT, NAS-score, liver transaminases or on markers of insulin resistance or inflammation."9.14Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. ( Birkeland, K; Bjøro, K; Eggesbø, HB; Haaland, T; Haukeland, JW; Konopski, Z; Løberg, EM; Raschpichler, G; von Volkmann, HL, 2009)
"Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated."9.11A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005)
"To examine the effect of metformin treatment during ischemia/reperfusion injury in fatty liver and determine the possible mechanisms."7.96Metformin Attenuates Ischemia-reperfusion Injury of Fatty Liver in Rats Through Inhibition of the TLR4/NF-κB Axis ( Huang, C; Li, X; Wang, L; Yang, X, 2020)
"Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders."7.91Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019)
" This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin."7.85Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017)
"We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats."7.83Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016)
" To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity."7.80Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014)
"To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet."7.77[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011)
" Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study."7.77Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011)
"To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD)."7.76Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. ( Bachyrycz, AM; Cone, CJ; Murata, GH, 2010)
"Our aim was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease."7.74The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. ( Aksoy, N; Akyüz, F; Beşişik, F; Boztaş, G; Cakaloğlu, Y; Cevikbaş, U; Demir, K; Ibrişim, D; Kaymakoğlu, S; Mungan, Z; Okten, A; Ozdil, S; Poturoğlu, S, 2007)
"A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)."7.74Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007)
"To explore the therapeutic effects of metformin on rat fatty livers induced by high fat feeding."7.73[Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding]. ( Dong, H; Gao, ZQ; Lu, FE; Wang, KF; Xu, LJ; Zhou, X, 2005)
"To investigate the effects of metformin on fatty livers in insulin-resistant rats."7.73[Effects of metformin on fatty liver in insulin-resistant rats]. ( Chen, SQ; Deng, JC; Liu, Q; Sun, H; Tang, L, 2005)
"To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)."7.73Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. ( Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006)
"Metformin treatment was associated with significant decrease in PWV and AI in NAFLD patients."6.76Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011)
" Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks."6.76Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011)
"Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)."6.74The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009)
"Metformin is an antidiabetic drug used widely in clinical practice."6.48Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012)
"Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan."6.43[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006)
"Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy."5.72Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022)
"Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models."5.72Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022)
"Metformin was treated daily for 14 weeks in a high-fat dieting C57BL/6J mice."5.43Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. ( Byun, JK; Cho, ML; Choi, JY; Jeong, JH; Jhun, JY; Kim, EK; Kim, JK; Lee, SH; Lee, SY, 2016)
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes."5.38Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012)
"There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease."5.31Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000)
"Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD."5.17Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. ( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013)
" Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial."5.16Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. ( Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R, 2012)
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3."5.15Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011)
"The presence of fatty liver per ultrasound and liver-associated enzymes were measured in a select cohort of youth with both obesity and insulin resistance, and the effect of metformin on these parameters evaluated."5.14Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. ( Ehlers, LB; Love-Osborne, K; Nadeau, KJ; Zeitler, PS, 2009)
"Non-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH."5.14Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. ( Borg, BB; Feld, JJ; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Loomba, R; Lutchman, G; Modi, A; Nagabhyru, P; Ricks, M; Sumner, AE, 2009)
"No significant differences between treatment with metformin or placebo were observed for changes in liver steatosis, assessed either histologically or by CT, NAS-score, liver transaminases or on markers of insulin resistance or inflammation."5.14Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. ( Birkeland, K; Bjøro, K; Eggesbø, HB; Haaland, T; Haukeland, JW; Konopski, Z; Løberg, EM; Raschpichler, G; von Volkmann, HL, 2009)
"In our 6-month prospective study, both low-dose metformin and dietary treatment alone ameliorated liver steatosis and metabolic derangements in patients with NAFLD."5.14Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. ( Abenavoli, L; Abenavoli, S; Belfiore, A; De Siena, M; Fruci, B; Garinis, GA; Greco, M; Gulletta, E; Mazza, A; Ventura, V, 2010)
"Previous studies demonstrated that in experimental animals fatty liver is associated with reduced hepatic blood flow and that metformin reverses steatosis, while no data were reported in humans."5.11Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. ( Berzigotti, A; Bianchi, G; Magalotti, D; Marchesini, G; Ramilli, S; Zoli, M, 2004)
"Open-label treatment with metformin for 24 weeks was notable for improvement in liver chemistry, liver fat, insulin sensitivity and quality of life."5.11A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. ( Deutsch, R; Lavine, JE; Middleton, MS; Schwimmer, JB, 2005)
"Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated."5.11A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005)
"A MEDLINE, Pubmed and Cochrane Review database search using a combination of keywords, which included non-alcoholic fatty liver disease, non-alcoholic hepatic steatosis, NAFLD, NASH, treatment, therapeutics, vitamin E, orlistat and bariatric surgery."4.90Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. ( Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM, 2014)
"Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries."4.88Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012)
" Metformin, a common therapeutic option for hyperglycemia in type 2 diabetes patients known to partially attenuate fatty liver, reduces the infection of human and hACE2 hepatocytes."4.12The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes. ( Azkargorta, M; Bravo, M; Delgado, TC; Egia-Mendikute, L; Eguileor Giné, A; Elortza, F; Ereño-Orbea, J; Gil-Pitarch, C; Goikoetxea-Usandizaga, N; González-Recio, I; Jiménez-Barbero, J; Jover, R; Lachiondo-Ortega, S; Lee, SY; Martínez-Chantar, ML; Martínez-Cruz, LA; Mercado-Gómez, M; Nogueiras, R; Palazon, A; Petrov, P; Prevot, V; Prieto-Fernández, E; Rodríguez-Agudo, R; Serrano-Maciá, M; Simón, J; Vila-Vecilla, L, 2022)
"To examine the effect of metformin treatment during ischemia/reperfusion injury in fatty liver and determine the possible mechanisms."3.96Metformin Attenuates Ischemia-reperfusion Injury of Fatty Liver in Rats Through Inhibition of the TLR4/NF-κB Axis ( Huang, C; Li, X; Wang, L; Yang, X, 2020)
"Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders."3.91Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019)
"Co-treatment with T317 and metformin inhibited the development of atherosclerosis without activation of lipogenesis, suggesting that combined treatment with T317 and metformin may be a novel approach to inhibition of atherosclerosis."3.88Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy. ( Chen, Y; Duan, Y; Feng, K; Han, J; Hu, W; Li, L; Li, X; Liu, L; Liu, Y; Ma, C; Miao, RQ; Sun, L; Yang, J; Yang, S; Yang, X; Yu, M; Zhang, W; Zhang, X; Zhu, Y, 2018)
" We were able to show in vivo that reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, protected mice from aging-dependent hepatic vesicular steatosis."3.88Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. ( Belloni, L; Blandino, G; Di Cocco, S; Guerrieri, F; Levrero, M; Marra, F; Mori, F; Nunn, ADG; Pallocca, M; Pediconi, N; Piconese, S; Pulito, C; Sacconi, A; Salerno, D; Strano, S; Testoni, B; Vivoli, E, 2018)
"The present study aimed to investigate the effect of metformin on the induction of autophagy in the liver and adipose tissues of a mouse model of obesity."3.85Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice. ( Li, M; Sharma, A; Tan, X; Xiao, Y; Yin, C, 2017)
" This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin."3.85Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017)
"In addition to the ascertained efficacy as antidiabetic drug, metformin is increasingly being used as weight-loss agent in obesity, and as insulin sensitizer in nonalcoholic fatty liver disease (NAFLD)."3.83Metformin increases hepatic leptin receptor and decreases steatosis in mice. ( Cui, Y; Gan, L; Li, J; Tang, X; Wang, X; Xiang, W; Xie, B; Xu, Z, 2016)
"We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats."3.83Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016)
"Here, we sought to compare the efficacy of combining exercise and metformin for the treatment of type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) in hyperphagic, obese, type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats."3.80Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. ( Booth, FW; Crissey, JM; Fletcher, JA; Ibdah, JA; Kearney, ML; Laughlin, MH; Linden, MA; Meers, GM; Morris, EM; Rector, RS; Sowers, JR; Thyfault, JP, 2014)
" To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity."3.80Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014)
"The administration of a HFD induces insulin resistance in the liver sinusoidal endothelium, which is mediated, at least in part, through iNOS upregulation and can be prevented by the administration of metformin."3.77Insulin resistance and liver microcirculation in a rat model of early NAFLD. ( Abraldes, JG; Bosch, J; García-Pagán, JC; La Mura, V; Pasarín, M; Rodríguez-Vilarrupla, A, 2011)
"To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet."3.77[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011)
" Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study."3.77Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011)
"To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD)."3.76Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. ( Bachyrycz, AM; Cone, CJ; Murata, GH, 2010)
" We followed the spontaneous evolution of liver steatosis and tested the therapeutic usefulness of metformin and fenofibrate in a model of steatosis, the Zucker diabetic fatty (ZDF) rat."3.75Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. ( Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G, 2009)
"Our aim was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease."3.74The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. ( Aksoy, N; Akyüz, F; Beşişik, F; Boztaş, G; Cakaloğlu, Y; Cevikbaş, U; Demir, K; Ibrişim, D; Kaymakoğlu, S; Mungan, Z; Okten, A; Ozdil, S; Poturoğlu, S, 2007)
"A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)."3.74Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007)
"To explore the therapeutic effects of metformin on rat fatty livers induced by high fat feeding."3.73[Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding]. ( Dong, H; Gao, ZQ; Lu, FE; Wang, KF; Xu, LJ; Zhou, X, 2005)
"To investigate the effects of metformin on fatty livers in insulin-resistant rats."3.73[Effects of metformin on fatty liver in insulin-resistant rats]. ( Chen, SQ; Deng, JC; Liu, Q; Sun, H; Tang, L, 2005)
"To investigate the therapeutic effects of insulin-sensitizing drugs, rosiglitazone and metformin, on nonalcoholic fatty liver disease (NAFLD)."3.73[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. ( Chen, WK; Wang, T; Zhang, DM; Zhang, GY; Zhong, HJ, 2006)
"To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)."3.73Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. ( Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006)
"In patients with type 2 diabetes who were inadequately controlled with metformin and sulphonylurea, we compared the glucose-lowering efficacy, cardiometabolic parameters and safety of two drugs, ipragliflozin, a sodium-glucose cotransporter-2 inhibitor, and sitagliptin, a dipeptidyl peptidase-4 inhibitor."3.30Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. ( Kang, SM; Lim, S; Sohn, M; Yun, HM, 2023)
"Metformin-treated girls gained more height per bone-age year and had less visceral and hepatic fat."2.87Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation. ( de Zegher, F; García Beltrán, C; Ibáñez, L; López-Bermejo, A, 2018)
"Individuals with type 2 diabetes (n = 44) and glycated hemoglobin ≤ 7."2.80Effect of vildagliptin on hepatic steatosis. ( Al-Mrabeh, A; Foley, JE; Hollingsworth, KG; Macauley, M; Schweizer, A; Smith, FE; Taylor, R; Thelwall, PE, 2015)
"Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7."2.80Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. ( Castel, H; Chartrand, G; Chiasson, JL; de Guise, J; Gilbert, G; Julien, AS; Massicotte-Tisluck, K; Olivié, D; Rabasa-Lhoret, R; Soulez, G; Tang, A; Wartelle-Bladou, C, 2015)
"Pioglitazone was more effective than glibenclamide in improving inflammation and hepatic steatosis indices."2.78Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. ( D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T, 2013)
"Fetuin A levels were elevated in NAFLD."2.77Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. ( Aasheim, ET; Aukrust, P; Birkeland, KI; Dahl, TB; Gladhaug, IP; Haaland, T; Halvorsen, B; Haukeland, JW; Johansen, OE; Konopski, Z; Løberg, EM; Wium, C; Yndestad, A, 2012)
"Metformin treatment was associated with significant decrease in AI during one year treatment in NAFLD patients."2.77Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? ( Boaz, M; Gavish, D; Matas, Z; Omelchenko, E; Shargorodsky, M, 2012)
"Patients with treatment-naive type 2 diabetes (N = 16) were treated with insulin and metformin for a 3-month lead-in period, then assigned triple oral therapy (metformin, glyburide, and pioglitazone) or continued treatment with insulin and metformin."2.77Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. ( Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS, 2012)
"Metformin treatment was associated with significant decrease in PWV and AI in NAFLD patients."2.76Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011)
" Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks."2.76Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011)
"Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)."2.74The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009)
"The increased risk of type 2 diabetes and cardiovascular disease in PCOS is closely associated with BMI."2.55Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. ( Andersen, M; Glintborg, D, 2017)
"Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance."2.50The therapy of insulin resistance in other diseases besides type 2 diabetes. ( Barbaro, V; Dicembrini, I; Pala, L; Rotella, CM, 2014)
"Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide."2.49Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013)
"Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in hepatocytes in the absence of excessive alcohol intake, ranging in severity from simple steatosis to nonalcoholic steatohepatitis (NASH)."2.49Pharmacologic therapy for nonalcoholic fatty liver disease in adults. ( Bell, AM; Byrd, JS; Malinowski, SS; Riche, DM; Wofford, MR, 2013)
"Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis."2.49Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. ( Baldelli, E; Carulli, L; George, J; Hebbard, L; Loria, P; Maurantonio, M, 2013)
"Metformin is an antidiabetic drug used widely in clinical practice."2.48Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012)
"Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk."2.47[Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011)
"Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease worldwide."2.47Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. ( Ismail, MH, 2011)
"Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world."2.47Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011)
"Insulin resistance is a new target in the challenging management of chronic hepatitis C."2.46Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. ( del Campo, JA; López, RA; Romero-Gómez, M, 2010)
"Insulin resistance is nearly universal in NASH and is thought to play an important role in its pathogenesis leading to dysregulated lipid metabolism."2.45Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. ( Dong, MH; Loomba, R; Stein, LL, 2009)
"Early stages of fatty liver are clinically silent and include elevation of ALT and GGTP, hyperechogenic liver in USG and/or hepatomegaly."2.44[Non-alcoholic fatty liver disease--new view]. ( Lawniczak, M; Marlicz, W; Miezyńska-Kurtycz, J; Milkiewicz, P; Raszeja-Wyszomirska, J, 2008)
"Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America."2.44Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007)
"Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highly-active antiretroviral therapy) - associated lipodystrophy."2.43The fatty liver and insulin resistance. ( Westerbacka, J; Yki-Järvinen, H, 2005)
"Non-alcoholic steatohepatitis once considered a benign process is now known to lead to progressive fibrosis and cirrhosis."2.43Review article: Drug therapy for non-alcoholic fatty liver disease. ( Comar, KM; Sterling, RK, 2006)
"Insulin resistance is an integral part of the underlying pathophysiology in most patients with nonalcoholic fatty liver disease (NAFLD)."2.43Therapy of NAFLD: insulin sensitizing agents. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH, 2006)
"Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan."2.43[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006)
"Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus."2.43Metformin beyond diabetes: new life for an old drug. ( Mannucci, E; Monami, M; Rotella, CM, 2006)
"Metformin, a biguanide, has been available in the US for the treatment of type 2 diabetes mellitus for nearly 8 years."2.42Metformin: new understandings, new uses. ( Hundal, RS; Inzucchi, SE, 2003)
"Metformin therapy was found to eliminate fatty liver disease in this model."2.42Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. ( Barkin, JS; Hookman, P, 2003)
"Dulaglutide is approved in type 2 diabetes as a hypoglycemic agent."1.91Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism. ( Chen, H; Huang, H; Liu, Y; Zheng, S, 2023)
"Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy."1.72Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022)
"Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models."1.72Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022)
"Metformin was treated daily for 14 weeks in a high-fat dieting C57BL/6J mice."1.43Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. ( Byun, JK; Cho, ML; Choi, JY; Jeong, JH; Jhun, JY; Kim, EK; Kim, JK; Lee, SH; Lee, SY, 2016)
"From the 479 patients with NAFLD assessed, 302 patients (63%) greater than 18 years old were included."1.39NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. ( Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S, 2013)
"Metformin has recently drawn attention because of its potential antitumor effect."1.39Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. ( Aoki, K; Atsumi, T; Inoue, H; Ito, Y; Kaji, M; Nagashima, Y; Nakamura, A; Orime, K; Sakamoto, E; Sato, K; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y, 2013)
"Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues."1.38Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease. ( Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C, 2012)
"Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance."1.38Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin. ( Korbut, R; Madej, J; Okoń, K; Olszanecki, R; Stachowicz, A; Suski, M, 2012)
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes."1.38Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012)
"non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress."1.37Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. ( Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R, 2011)
"There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease."1.31Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000)
"There is no established treatment for steatohepatitis in patients who are not alcoholics."1.31Metformin in non-alcoholic steatohepatitis. ( Bianchi, G; Brizi, M; Marchesini, G; Melchionda, N; Tomassetti, S; Zoli, M, 2001)

Research

Studies (166)

TimeframeStudies, this research(%)All Research%
pre-19904 (2.41)18.7374
1990's1 (0.60)18.2507
2000's57 (34.34)29.6817
2010's95 (57.23)24.3611
2020's9 (5.42)2.80

Authors

AuthorsStudies
Ma, L1
Xie, C1
Ran, Y1
Liang, X2
Huang, L1
Pei, H1
Chen, J1
Liu, J3
Sang, Y1
Lai, H1
Peng, A1
Xiang, M1
Wei, Y1
Chen, L6
Mercado-Gómez, M1
Prieto-Fernández, E1
Goikoetxea-Usandizaga, N1
Vila-Vecilla, L1
Azkargorta, M1
Bravo, M1
Serrano-Maciá, M1
Egia-Mendikute, L1
Rodríguez-Agudo, R1
Lachiondo-Ortega, S1
Lee, SY2
Eguileor Giné, A1
Gil-Pitarch, C1
González-Recio, I1
Simón, J1
Petrov, P1
Jover, R1
Martínez-Cruz, LA1
Ereño-Orbea, J1
Delgado, TC1
Elortza, F1
Jiménez-Barbero, J1
Nogueiras, R1
Prevot, V1
Palazon, A1
Martínez-Chantar, ML1
Reifsnyder, PC1
Flurkey, K1
Doty, R1
Calcutt, NA1
Koza, RA1
Harrison, DE1
Schoonejans, JM1
Blackmore, HL1
Ashmore, TJ1
Pantaleão, LC1
Pellegrini Pisani, L1
Dearden, L1
Tadross, JA1
Aiken, CE1
Fernandez-Twinn, DS1
Ozanne, SE1
Kang, SM2
Yun, HM1
Sohn, M1
Lim, S2
Zheng, S1
Huang, H1
Chen, H1
Liu, Y2
Adeshirlarijaney, A1
Zou, J1
Tran, HQ1
Chassaing, B1
Gewirtz, AT1
Li, X2
Wang, L1
Yang, X3
Huang, C1
Liu, Q2
Li, L3
Gao, L1
Li, C1
Huan, Y1
Lei, L1
Cao, H1
Gao, A1
Liu, S1
Shen, Z1
de Zegher, F2
Díaz, M1
Villarroya, J1
Cairó, M1
López-Bermejo, A2
Villarroya, F1
Ibáñez, L2
Zhang, X2
Zhuang, Y1
Qin, T1
Chang, M1
Ji, X1
Wang, N1
Zhang, Z1
Zhou, H1
Wang, Q1
Li, JZ1
Li, M2
Sharma, A1
Yin, C1
Tan, X1
Xiao, Y1
Kosi-Trebotic, L1
Thomas, A1
Harreiter, J1
Chmelik, M1
Trattnig, S1
Kautzky-Willer, A1
Glintborg, D1
Andersen, M1
Choi, RY1
Ham, JR1
Lee, HI1
Cho, HW1
Choi, MS1
Park, SK1
Lee, J1
Kim, MJ1
Seo, KI1
Lee, MK1
García Beltrán, C1
Boudaba, N1
Marion, A1
Huet, C1
Pierre, R1
Viollet, B1
Foretz, M1
Ma, C1
Zhang, W1
Liu, L1
Feng, K1
Yang, S1
Sun, L1
Yu, M1
Yang, J1
Hu, W1
Miao, RQ1
Zhu, Y1
Han, J1
Chen, Y1
Duan, Y1
Chang, HH1
Moro, A1
Chou, CEN1
Dawson, DW1
French, S1
Schmidt, AI1
Sinnett-Smith, J1
Hao, F1
Hines, OJ1
Eibl, G1
Rozengurt, E1
Zabielski, P1
Hady, HR1
Chacinska, M1
Roszczyc, K1
Gorski, J1
Blachnio-Zabielska, AU1
Belloni, L1
Di Cocco, S1
Guerrieri, F1
Nunn, ADG1
Piconese, S1
Salerno, D1
Testoni, B1
Pulito, C1
Mori, F1
Pallocca, M1
Sacconi, A1
Vivoli, E1
Marra, F1
Strano, S1
Blandino, G1
Levrero, M1
Pediconi, N1
Zhang, C1
Hu, J1
Sheng, L1
Yuan, M1
Wu, Y1
Zheng, G1
Qiu, Z1
Treeprasertsuk, S1
Björnsson, E1
Enders, F1
Suwanwalaikorn, S1
Lindor, KD1
Maffioli, P1
Fogari, E1
D'Angelo, A1
Perrone, T1
Derosa, G1
Tajima, K1
Nakamura, A1
Shirakawa, J1
Togashi, Y1
Orime, K1
Sato, K1
Inoue, H1
Kaji, M1
Sakamoto, E1
Ito, Y1
Aoki, K1
Nagashima, Y1
Atsumi, T1
Terauchi, Y1
Younossi, ZM1
Reyes, MJ1
Mishra, A1
Mehta, R1
Henry, L1
Liu, F1
Wang, C2
Zhang, L1
Xu, Y3
Jang, L1
Gu, Y1
Cao, X1
Zhao, X1
Ye, J1
Li, Q2
Fruci, B3
Giuliano, S2
Mazza, A3
Malaguarnera, R2
Belfiore, A3
Mazzella, N1
Ricciardi, LM1
Mazzotti, A1
Marchesini, G7
Linden, MA1
Fletcher, JA1
Morris, EM1
Meers, GM1
Kearney, ML1
Crissey, JM1
Laughlin, MH1
Booth, FW1
Sowers, JR1
Ibdah, JA1
Thyfault, JP1
Rector, RS1
Fan, H1
Pan, Q1
Hong, ES1
Kim, EK2
Khang, AR1
Choi, SH1
Park, KS1
Jang, HC1
Woo, SL1
Xu, H1
Li, H1
Zhao, Y1
Hu, X1
Zhao, J1
Guo, X1
Guo, T1
Botchlett, R1
Qi, T1
Pei, Y1
Zheng, J1
An, X1
Xiao, X1
Huo, Y1
Wu, C1
Shu, Y1
Chen, EC1
Yee, SW2
Zur, AA1
Li, S1
Xu, L1
Keshari, KR1
Lin, MJ1
Chien, HC1
Zhang, Y2
Morrissey, KM1
Ostrem, J1
Younger, NS1
Kurhanewicz, J1
Shokat, KM1
Ashrafi, K1
Giacomini, KM2
Yang, L1
Song, MQ1
Zhang, QL1
Shou, L1
Zang, SF1
Yang, YL1
Pala, L1
Barbaro, V1
Dicembrini, I1
Rotella, CM2
Song, YM2
Lee, YH2
Kim, JW1
Ham, DS1
Kang, ES2
Cha, BS2
Lee, HC1
Lee, BW2
Macauley, M1
Hollingsworth, KG2
Smith, FE1
Thelwall, PE1
Al-Mrabeh, A1
Schweizer, A1
Foley, JE1
Taylor, R2
Tang, A1
Rabasa-Lhoret, R1
Castel, H1
Wartelle-Bladou, C1
Gilbert, G1
Massicotte-Tisluck, K1
Chartrand, G1
Olivié, D1
Julien, AS1
de Guise, J1
Soulez, G1
Chiasson, JL1
Cassidy, S1
Thoma, C1
Hallsworth, K1
Parikh, J1
Jakovljevic, DG1
Trenell, MI1
Wang, FZ1
Xie, ZS1
Xing, L1
Zhang, BF1
Zhang, JL1
Cui, PF1
Qiao, JB1
Shi, K1
Cho, CS1
Cho, MH1
Xu, X1
Li, P1
Jiang, HL1
Kutbay, NO1
Yurekli, BS1
Onay, H1
Altay, CT1
Atik, T1
Hekimsoy, Z1
Saygili, F1
Akinci, B1
Lee, WK1
García-Heredia, A1
Riera-Borrull, M1
Fort-Gallifa, I1
Luciano-Mateo, F1
Cabré, N1
Hernández-Aguilera, A1
Joven, J1
Camps, J1
Meng, X1
Guo, J1
Fang, W1
Dou, L1
Huang, X1
Zhou, S1
Man, Y1
Tang, W1
Yu, L1
Li, J2
Lee, SH1
Jhun, JY1
Byun, JK1
Jeong, JH1
Kim, JK1
Choi, JY1
Cho, ML1
Tang, X1
Xiang, W1
Cui, Y1
Xie, B1
Wang, X1
Xu, Z1
Gan, L1
Lu, CH1
Hung, YJ1
Hsieh, PS1
Mubeen, S1
Amjad, Z1
Memon, FM1
Ashraf, SU1
Takemori, H1
Fu, J1
Xu, M1
Xiong, L1
Li, N2
Wen, X1
Nobili, V3
Manco, M1
Ciampalini, P1
Alisi, A2
Devito, R1
Bugianesi, E3
Marcellini, M1
Raszeja-Wyszomirska, J1
Lawniczak, M1
Marlicz, W1
Miezyńska-Kurtycz, J1
Milkiewicz, P1
Nadeau, KJ1
Ehlers, LB1
Zeitler, PS1
Love-Osborne, K1
Nar, A1
Gedik, O1
Loomba, R2
Lutchman, G1
Kleiner, DE2
Ricks, M1
Feld, JJ1
Borg, BB1
Modi, A1
Nagabhyru, P1
Sumner, AE1
Liang, TJ1
Hoofnagle, JH2
Kashi, MR1
Torres, DM2
Harrison, SA2
Patton, HM1
Lavine, JE8
Van Natta, ML2
Schwimmer, JB6
Kleiner, D1
Molleston, J1
Vuppalanchi, R1
Chalasani, N5
Raso, GM1
Esposito, E1
Iacono, A1
Pacilio, M1
Cuzzocrea, S1
Canani, RB1
Calignano, A1
Meli, R1
Fischer, R1
Shneider, B1
Mascitelli, L1
Pezzetta, F1
Goldstein, MR1
Socha, P2
Horvath, A1
Vajro, P1
Dziechciarz, P1
Dhawan, A1
Szajewska, H1
Forcheron, F1
Abdallah, P1
Basset, A1
del Carmine, P1
Haffar, G1
Beylot, M1
Omer, Z1
Cetinkalp, S1
Akyildiz, M1
Yilmaz, F1
Batur, Y1
Yilmaz, C1
Akarca, U1
Molleston, JP2
Scheimann, AO2
Murray, KF2
Abrams, SH2
Rosenthal, P2
Sanyal, AJ3
Robuck, PR2
Brunt, EM3
Unalp, A2
Tonascia, J2
Haukeland, JW2
Konopski, Z2
Eggesbø, HB1
von Volkmann, HL1
Raschpichler, G1
Bjøro, K1
Haaland, T2
Løberg, EM2
Birkeland, K1
Stein, LL1
Dong, MH1
Jin, X1
Yu, CH1
Chen, SH1
Li, WP1
Li, YM1
Garinis, GA2
De Siena, M1
Abenavoli, S1
Gulletta, E1
Ventura, V1
Greco, M1
Abenavoli, L3
Krakoff, J1
Clark, JM2
Crandall, JP1
Wilson, C1
Molitch, ME1
Brancati, FL1
Edelstein, SL1
Knowler, WC1
del Campo, JA1
López, RA1
Romero-Gómez, M1
Tharayil, V1
Roberts, LR1
Cone, CJ1
Bachyrycz, AM1
Murata, GH1
Brouwers, MC1
de Graaf, J1
van Greevenbroek, MM1
Schaper, N1
Stehouwer, CD1
Stalenhoef, AF1
Rakoski, MO1
Singal, AG1
Rogers, MA1
Conjeevaram, H1
Ratziu, V1
Caldwell, S1
Neuschwander-Tetri, BA1
González Jiménez, E1
Schmidt Río-Valle, J1
Álvarez Ferre, J1
Matafome, P1
Louro, T1
Rodrigues, L1
Crisóstomo, J1
Nunes, E1
Amaral, C1
Monteiro, P1
Cipriano, A1
Seiça, R1
Pasarín, M1
Abraldes, JG1
Rodríguez-Vilarrupla, A1
La Mura, V1
García-Pagán, JC1
Bosch, J1
Brufani, C1
Fintini, D1
Patera, PI1
Cappa, M1
Brufani, M1
Sofer, E1
Boaz, M2
Matas, Z2
Mashavi, M1
Shargorodsky, M2
Ismail, MH1
Huang, Y1
Fu, JF1
Shi, HB1
Liu, LR1
Li, Y1
Xu, S1
Mihaylova, MM1
Zheng, B1
Hou, X1
Jiang, B1
Park, O1
Luo, Z1
Lefai, E1
Shyy, JY1
Gao, B1
Wierzbicki, M1
Verbeuren, TJ1
Shaw, RJ1
Cohen, RA1
Zang, M1
Sharif, A1
Pacifico, L1
Anania, C1
Martino, F1
Poggiogalle, E1
Chiarelli, F1
Arca, M1
Chiesa, C1
Jones, FJ1
Shaw, JC1
Williams, CD1
Ward, JA1
Sookoian, S1
Pirola, CJ1
Retnakaran, R1
Ye, C1
Hanley, AJ1
Harris, SB1
Zinman, B1
Corey, KE1
Samson, SL1
Sathyanarayana, P1
Jogi, M1
Gonzalez, EV1
Gutierrez, A1
Krishnamurthy, R1
Muthupillai, R1
Chan, L1
Bajaj, M1
Shyangdan, D1
Clar, C1
Ghouri, N1
Henderson, R1
Gurung, T1
Preiss, D1
Sattar, N1
Fraser, A1
Waugh, N1
Andrews, DB1
Dahl, TB1
Yndestad, A1
Gladhaug, IP1
Wium, C1
Aasheim, ET1
Johansen, OE1
Aukrust, P1
Halvorsen, B1
Birkeland, KI1
Weickert, MO1
Hodges, P1
Tan, BK1
Randeva, HS1
Younossi, Z1
Diehl, AM2
Cusi, K1
Charlton, M1
Barbero-Becerra, VJ1
Santiago-Hernandez, JJ1
Villegas-Lopez, FA1
Mendez-Sanchez, N1
Uribe, M2
Chavez-Tapia, NC2
Janczyk, W1
Spruss, A1
Kanuri, G1
Stahl, C1
Bischoff, SC1
Bergheim, I1
Akcam, M1
Boyaci, A1
Pirgon, O1
Kaya, S1
Uysal, S1
Dundar, BN1
Omelchenko, E1
Gavish, D1
Bozzetto, L1
Prinster, A1
Annuzzi, G1
Costagliola, L1
Mangione, A1
Vitelli, A1
Mazzarella, R1
Longobardo, M1
Mancini, M1
Vigorito, C1
Riccardi, G1
Rivellese, AA1
Lingvay, I1
Roe, ED1
Duong, J1
Leonard, D1
Szczepaniak, LS1
Stachowicz, A1
Suski, M1
Olszanecki, R1
Madej, J1
Okoń, K1
Korbut, R1
Kita, Y1
Takamura, T1
Misu, H1
Ota, T1
Kurita, S1
Takeshita, Y1
Uno, M1
Matsuzawa-Nagata, N1
Kato, K1
Ando, H1
Fujimura, A1
Hayashi, K1
Kimura, T1
Ni, Y1
Otoda, T1
Miyamoto, K1
Zen, Y1
Nakanuma, Y1
Kaneko, S1
Su, X1
Gi, YJ1
Chakravarti, D1
Chan, IL1
Zhang, A1
Xia, X1
Tsai, KY1
Flores, ER1
Lanaspa, MA1
Cicerchi, C1
Garcia, G1
Roncal-Jimenez, CA1
Rivard, CJ1
Hunter, B1
Andrés-Hernando, A1
Ishimoto, T1
Sánchez-Lozada, LG1
Thomas, J1
Hodges, RS1
Mant, CT1
Johnson, RJ1
Resuli, B1
Demiraj, V1
Babameto, A1
Sema, K1
Malaj, V1
Panahi, Y1
Ghamarchehreh, ME1
Beiraghdar, F1
Zare, R1
Jalalian, HR1
Sahebkar, A1
Chen, YM1
Liao, YJ1
Malinowski, SS1
Byrd, JS1
Bell, AM1
Wofford, MR1
Riche, DM1
Carulli, L1
Maurantonio, M1
Hebbard, L1
Baldelli, E1
Loria, P1
George, J1
Hookman, P2
Barkin, JS2
Hundal, RS1
Inzucchi, SE1
Kadayifçi, A2
Magalotti, D1
Ramilli, S1
Berzigotti, A1
Bianchi, G2
Zoli, M2
Marzocchi, R1
Villanova, N2
Gao, ZQ1
Lu, FE1
Dong, H1
Xu, LJ1
Wang, KF1
Zhou, X1
Shen, W1
Middleton, MS1
Deutsch, R1
Gentilcore, E1
Manini, R2
Natale, S2
Vanni, E1
David, E1
Rizzetto, M1
Yki-Järvinen, H1
Westerbacka, J1
Moreno Sánchez, D1
Anania, FA2
Parekh, S1
Shaukat, A1
Agostini, F1
Kluwe, J1
Lohse, AW1
Chen, SQ1
Sun, H1
Tang, L1
Deng, JC1
Comar, KM1
Sterling, RK1
Caldwell, SH1
Argo, CK1
Al-Osaimi, AM1
Siebler, J1
Galle, PR1
Korenaga, M1
Kawaguchi, K1
Korenaga, K1
Uchida, K1
Sakaida, I1
Merriman, RB1
Zhang, DM1
Zhang, GY1
Wang, T1
Zhong, HJ1
Chen, WK1
Assy, N1
Grozovski, M1
Bersudsky, I1
Szvalb, S1
Hussein, O1
Tushuizen, ME1
Bunck, MC1
Pouwels, PJ1
van Waesberghe, JH1
Diamant, M1
Heine, RJ1
Hoppin, AG1
Katz, ES1
Kaplan, LM1
Lauwers, GY1
Barrientos-Gutierrez, T1
Tellez-Avila, FI1
Sanchez-Avila, F1
Montano-Reyes, MA1
Angelico, F1
Burattin, M1
Alessandri, C1
Del Ben, M1
Lirussi, F1
Hoteit, MA1
Schroeder-Gloeckler, JM1
Rahman, SM1
Janssen, RC1
Qiao, L1
Shao, J1
Roper, M1
Fischer, SJ1
Lowe, E1
Orlicky, DJ1
McManaman, JL1
Palmer, C1
Gitomer, WL1
Huang, W1
O'Doherty, RM1
Becker, TC1
Klemm, DJ1
Jensen, DR1
Pulawa, LK1
Eckel, RH1
Friedman, JE1
Akyüz, F1
Demir, K1
Ozdil, S1
Aksoy, N1
Poturoğlu, S1
Ibrişim, D1
Kaymakoğlu, S1
Beşişik, F1
Boztaş, G1
Cakaloğlu, Y1
Mungan, Z1
Cevikbaş, U1
Okten, A1
Bueverov, AO1
Bogomolov, PO1
Maevskaia, MV1
Khashab, M1
Sinha, SK1
Bhangoo, A1
Anhalt, H1
Maclaren, N1
Marshall, JD1
Collin, GB1
Naggert, JK1
Ten, S1
Monami, M1
Mannucci, E1
Targher, G1
Lippi, G1
Moghetti, P1
Idilman, R1
Mizrak, D1
Corapcioglu, D1
Bektas, M1
Doganay, B1
Sayki, M1
Coban, S1
Erden, E1
Soykan, I1
Emral, R1
Uysal, AR1
Ozden, A1
Krentz, AJ1
Lin, HZ1
Yang, SQ1
Chuckaree, C1
Kuhajda, F1
Ronnet, G1
Brizi, M1
Tomassetti, S1
Melchionda, N1
Urso, R1
Visco-Comandini, U1
Bischoff, A1
Marquie, G3
Agid, R2
Haese, E1

Clinical Trials (32)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy[NCT05301231]450 participants (Anticipated)Observational [Patient Registry]2022-08-01Not yet recruiting
A Single-center,Double-blind,Randomised,Placebo-controlled,Parallel-group Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin on Insulin Sensitivity and Its Underlying Mechanism in Patients With T2DM Treated With Metformin[NCT01356381]Phase 443 participants (Actual)Interventional2011-04-30Completed
Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study[NCT01399645]Phase 235 participants (Actual)Interventional2011-05-31Completed
Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance[NCT02045290]Phase 337 participants (Actual)Interventional2014-01-31Completed
A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828]Phase 3164 participants (Actual)Interventional2013-09-30Completed
Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study[NCT02457286]Phase 10 participants (Actual)Interventional2015-06-30Withdrawn (stopped due to patients do not want to participate)
A Pilot Study: Metformin as an Inflammatory Modulating Therapy in Older Adults Without Diabetes[NCT03772964]Phase 1/Phase 232 participants (Actual)Interventional2019-01-22Completed
Treatment of Nonalcoholic Steatohepatitis With Metformin[NCT00063232]Phase 228 participants (Actual)Interventional2003-06-30Completed
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571]1,080 participants (Anticipated)Observational2019-04-01Recruiting
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635]Phase 3173 participants (Actual)Interventional2005-09-30Completed
Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)[NCT00303537]Phase 2/Phase 390 participants (Anticipated)Interventional2004-11-30Active, not recruiting
[NCT01084486]Phase 1/Phase 20 participants InterventionalCompleted
Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405]Phase 424 participants (Actual)Interventional2007-06-30Completed
Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755]Phase 1/Phase 220 participants (Actual)Interventional2019-01-09Completed
Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis[NCT02526732]44 participants (Actual)Interventional2015-09-30Completed
The Effects of Type of Exercise on Hepatic Fat Content and Metabolic Profiles in Non-alcoholic Fatty Liver Disease: A Randomized Trial[NCT02679417]38 participants (Actual)Interventional2015-08-31Completed
A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH[NCT02933554]8 participants (Anticipated)Interventional2024-06-30Not yet recruiting
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and Nonalcoholic Steatohepatitis in Biopsy-Proven NAFLD Patients[NCT03725631]150 participants (Anticipated)Interventional2016-09-01Recruiting
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]Phase 4120 participants (Anticipated)Interventional2017-08-16Recruiting
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158]Phase 356 participants (Anticipated)Interventional2022-11-30Not yet recruiting
An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)[NCT02653300]Phase 210 participants (Actual)Interventional2018-09-20Completed
Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients[NCT04779905]62 participants (Actual)Observational2021-02-28Completed
Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)[NCT03375008]47 participants (Actual)Interventional2016-09-08Completed
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis[NCT03061721]Phase 2106 participants (Actual)Interventional2017-04-06Completed
A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04618744]Phase 233 participants (Actual)Interventional2020-11-24Completed
Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes[NCT01025856]45 participants (Actual)Interventional2009-09-30Completed
Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806]Phase 415 participants (Anticipated)Interventional2022-10-10Active, not recruiting
Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382]Phase 360 participants (Anticipated)Interventional2008-11-30Active, not recruiting
Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668]136 participants (Anticipated)Observational2021-04-10Recruiting
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]Phase 28 participants (Actual)Interventional2012-04-30Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018]Phase 2/Phase 390 participants (Actual)Interventional2003-01-31Completed
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)[NCT00845845]Phase 212 participants (Actual)Interventional2006-03-31Terminated (stopped due to Terminated due to low enrollment.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Body Composition

Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks

Interventionpercentage of change (Mean)
Metformin-0
Oral Placebo1

Change in Body Mass Index (BMI)

(NCT01881828)
Timeframe: 0-26 weeks

Interventionpercentile (Mean)
Metformin-1
Oral Placebo1

Change in Total Daily Dose of Insulin (TDI) Per kg

(NCT01881828)
Timeframe: 0-26 weeks

Interventioninsulin per kg (Mean)
Metformin-0.1
Oral Placebo-0.0

Change in Waist Circumference

(NCT01881828)
Timeframe: 0-26 weeks

Interventioncentimeters (Mean)
Metformin-0
Oral Placebo1

Change in Blood Pressure

(NCT01881828)
Timeframe: 0-26 weeks

,
Interventionmm Hg (Mean)
Change in SystolicChange in Diastolic
Metformin00
Oral Placebo-00

Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.

Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks

,
Interventionpercentage (Mean)
HbA1cChange from Baseline to 26 Weeks
Metformin9.00.2
Oral Placebo8.90.2

Change in Hemoglobin A1c From Baseline to 26 Weeks, Adjusted for Baseline Hemoglobin A1c.

Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks

,
Interventionpercentage of participants (Number)
HbA1c Decrease ≥0.5%HbA1c Increase ≥0.5%HbA1c <7.5%
Metformin19443
Oral Placebo18354

Change in Serum Lipids

(NCT01881828)
Timeframe: 0-26 weeks

,
Interventionmg/dL (Mean)
Change in LDLChange in VLDLChange in HDLChange in TriglyceridesChange in Total Cholesterol
Metformin-6-0-04-5
Oral Placebo21-163

Changes From Baseline in Grip Strength Via a Dynamometer During and Following Exposure to Metformin.

Grip strength over time. (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)

,,,
InterventionmmHg (Mean)
0 days90 days, compared to 0 days120 days, compared to 0 days
1000mg Exposure28.9-0.41.1
1500mg Exposure25.7-.2.3
500mg Exposure28.2-5.3.1
Placebo25.7-.3-.6

Changes From Baseline in Short Physical Performance Battery (SPPB) During and Following Exposure to Metformin.

The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The minimum is zero (worse performance) and the maximum is 12 (best performance). (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)

,,,
InterventionUnits on a scale (Mean)
0d90d, change from 0d120d, change from 0d
1000mg Exposure10.80.40.2
1500mg Exposure11.10.40.3
500mg Exposure11.2-0.30
Placebo10.61.00.5

Measure the Rate of Clotting of Peripheral Blood With Whole Blood Aggregometry in Response to Collagen.

Aggregometry area under the curve with the Y-axis being % aggregometry and the X-axis time in minutes. (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)

,,,
Interventionarbitrary units*mins (Mean)
0 days30 day change from day 060 days change from day 090 days change from day 0120 days change from day 0
1000mg Exposure678.9-23.52.41.0
1500mg Exposure196-166.7-139.8-222.5-196.7
500mg Exposure56.3-34.7-28.31.6-49.2
Placebo83.3-29.6-49.4-66.6-47.6

Quantify the Bacterial Population Profile of the Microbiome Via Stool Samples.

"Bacterial communities using 16S rRNA sequencing in relationship to metformin dosing over time. Species richness or diversity in the sample is measured by Choa1 metric. Chao1 is an estimate of how many species are present in an ecosystem. In general, having more species is considered to be healthier and these values typically range from 100-200 for fecal samples. The Chao1 index over numerous samples across time are explored to understand treatment effects." (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)

,,,
InterventionIndex (Mean)
Day 0Day 30Day 60Day 90Day 120
1000mg Exposure107.6130.7137.9135142.2
1500mg Exposure128.1128.1128.6138.2144.2
500mg Exposure136.5139.9121.4137.8134
Placebo141.5144.75134.3152159.2

Change in Insulin Sensitivity (Glucose Tolerance, Homeostatic Model Assessment of Insulin Resistence (HOMA-IR)) From Baseline

HOMA-IR is calculated from Fasting Glucose and Fasting Insulin (NCT00063232)
Timeframe: from baseline to 48 weeks

Interventionunit (Mean)
Metformin-3.3

Change in Serum Alanine Aminotransferase (ALT) Levels From Baseline (Number of Participants in Each Change Category)

Alanine transaminase <42 U/L is considered normal (NCT00063232)
Timeframe: from baseline to 48 weeks

Interventionparticipants (Number)
changed to normal from abnormalunchanged (normal at beginning)unchanged (abnormal at beginning)changed to abnormal from normal
Metformin94121

Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category)

Patients under went liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint is a three point improvement in the histological NASH activity index with a decrease in at least two of the component scores and no worsening of fibrosis or increase in Mallory bodies. (NCT00063232)
Timeframe: from baseline to 48 Weeks

Interventionparticipants (Number)
improved (reduced) by greater or equal to 3 pointsimproved (reduced) by 1-2 pointsno changeworsen (increased)
Metformin91151

Change in Body Mass Index

(NCT00063635)
Timeframe: baseline and 96 weeks

Interventionkg/m-squared (Mean)
Metformin1.3
Vitamin E2.1
Placebo1.9

Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment

Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionunits on a scale (Mean)
Metformin-1.1
Vitamin E-1.8
Placebo-0.7

Change in QOL- Psychosocial Health

Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionunits on a scale (Mean)
Metformin4.0
Vitamin E6.0
Placebo5.6

Change in Quality of Life (QOL) Scores- Physical Health

Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionunits on a scale (Mean)
Metformin5.4
Vitamin E7.6
Placebo5.4

Change in Serum Aspartate Aminotransferase (AST)

(NCT00063635)
Timeframe: baseline and 96 weeks

InterventionIU/L (Mean)
Metformin-21.5
Vitamin E-22.8
Placebo-20.4

Change in Serum Vitamin E Levels

Change in alpha-Tocopherol (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionmg/L (Mean)
Metformin-0.5
Vitamin E9.4
Placebo-0.9

Number of Participants With Improvement in Ballooning Degradation Score

Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin22
Vitamin E22
Placebo10

Number of Participants With Improvement in Liver Fibrosis Score

Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin22
Vitamin E18
Placebo19

Number of Participants With Improvement in Lobular Inflammation Score

Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin23
Vitamin E22
Placebo20

Number of Participants With Improvement in Steatosis Score

Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin26
Vitamin E27
Placebo19

Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L

The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks

Interventionparticipants (Number)
Metformin9
Vitamin E15
Placebo10

Hepatic Fat

The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year

Interventionpercent of liver fat (Mean)
Pioglitazone and Exenatide4.7
Pioglitazone6.5

Plasma Adipocytokines

the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year

Interventionmicrogram per ml (Mean)
Pioglitazone and Exenatide23.2
Pioglitazone15.8

Change in MRI-Proton Density Fat Fraction (MRI-PDFF)

Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12 (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12

Interventionpercentage fat in the liver (Mean)
MRPDFF (%) at baselineMR PDFF (%) at Week 12Absolute Mean Change in MR PDFF (%) from Baseline
Oral Insulin21.314.4-6.9

Mean Fibrosis Score CAP™ (FibroMax)

Mean fibrosis score (severity scale of liver fibrosis) measured at baseline and week 12. Fibrosis Score CAP measures the amount of steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m with higher values indicating more fatty change (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12

InterventiondB/M (Mean)
Mean Fibrosis Score at BaselineMean Fibrosis Score at week 12
Oral Insulin338.5315.5

Mean Transient Elastography Measurement (Fibroscan)

Mean Transient elasticity, measured in kPA (kilo Pascal), (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12

InterventionkPa (Mean)
BaselineWeek 12
Oral Insulin8.67.4

Reviews

42 reviews available for metformin and Fatty Liver

ArticleYear
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review.
    Current opinion in obstetrics & gynecology, 2017, Volume: 29, Issue:6

    Topics: Body Mass Index; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fatty Liver; Femal

2017
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1

    Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Me

2014
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
    International journal of molecular sciences, 2013, Nov-20, Volume: 14, Issue:11

    Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re

2013
The role of medications for the management of patients with NAFLD.
    Clinics in liver disease, 2014, Volume: 18, Issue:1

    Topics: Antioxidants; Fatty Liver; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Me

2014
The therapy of insulin resistance in other diseases besides type 2 diabetes.
    Eating and weight disorders : EWD, 2014, Volume: 19, Issue:3

    Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic

2014
[Non-alcoholic fatty liver disease--new view].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 24, Issue:144

    Topics: Biopsy; Causality; Comorbidity; Disease Progression; Fatty Liver; Humans; Hyperglycemia; Insulin Res

2008
Current and emerging therapies in nonalcoholic fatty liver disease.
    Seminars in liver disease, 2008, Volume: 28, Issue:4

    Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics

2008
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1

    Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type

2009
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
    Journal of pediatric gastroenterology and nutrition, 2009, Volume: 48, Issue:5

    Topics: Acetylcysteine; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Dietary

2009
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Advances in therapy, 2009, Volume: 26, Issue:10

    Topics: Fatty Liver; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metf

2009
Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.
    Digestive diseases (Basel, Switzerland), 2010, Volume: 28, Issue:1

    Topics: Animals; Antiviral Agents; Diabetes Mellitus, Type 2; Fatty Liver; Glucose Clamp Technique; Hepatiti

2010
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
    Current opinion in lipidology, 2010, Volume: 21, Issue:6

    Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr

2010
Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:10

    Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic;

2010
Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:6

    Topics: Clinical Trials as Topic; Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Met

2010
[Fatty liver and its clinical management in obese adolescents].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2011, Volume: 58, Issue:1

    Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros

2011
Use of metformin in pediatric age.
    Pediatric diabetes, 2011, Volume: 12, Issue:6

    Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty

2011
Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic.
    The American journal of the medical sciences, 2011, Volume: 341, Issue:6

    Topics: Bariatric Surgery; Biopsy; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Fatty Liver; Hu

2011
Management of metabolic syndrome in children and adolescents.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2011, Volume: 21, Issue:6

    Topics: Adolescent; Antioxidants; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Diabet

2011
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:38

    Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents;

2011
The role of metformin in the management of NAFLD.
    Experimental diabetes research, 2012, Volume: 2012

    Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin

2012
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
    Minerva endocrinologica, 2012, Volume: 37, Issue:1

    Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones;

2012
Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease.
    Current medicinal chemistry, 2012, Volume: 19, Issue:18

    Topics: Animals; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Non-alcoholic Fatty Liver Disea

2012
Pharmacologic therapy for nonalcoholic fatty liver disease in adults.
    Pharmacotherapy, 2013, Volume: 33, Issue:2

    Topics: Adult; Animals; Disease Progression; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi

2013
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.
    Current pharmaceutical design, 2013, Volume: 19, Issue:29

    Topics: Carcinoma, Hepatocellular; Child; Fatty Liver; Humans; Hypoglycemic Agents; Liver Neoplasms; Metform

2013
Metformin: new understandings, new uses.
    Drugs, 2003, Volume: 63, Issue:18

    Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I

2003
Metformin: new understandings, new uses.
    Drugs, 2003, Volume: 63, Issue:18

    Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I

2003
Metformin: new understandings, new uses.
    Drugs, 2003, Volume: 63, Issue:18

    Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I

2003
Metformin: new understandings, new uses.
    Drugs, 2003, Volume: 63, Issue:18

    Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I

2003
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:9

    Topics: Adult; Animals; Biochemical Phenomena; Biochemistry; Biopsy, Needle; Clinical Trials as Topic; Disea

2003
Nonalcoholic fatty liver disease in the pediatric population.
    Clinics in liver disease, 2004, Volume: 8, Issue:3

    Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Female; Histocytochemistry; Humans; Hypoglycem

2004
Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
    Best practice & research. Clinical gastroenterology, 2004, Volume: 18, Issue:6

    Topics: Antioxidants; Cholagogues and Choleretics; Cytoprotection; Enzyme Inhibitors; Fatty Liver; Humans; H

2004
The fatty liver and insulin resistance.
    Current molecular medicine, 2005, Volume: 5, Issue:3

    Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Animals; Antiretroviral Therapy, Highly Active; C

2005
[Medical management of primary nonalcoholic fatty liver disease].
    Medicina clinica, 2005, Jun-18, Volume: 125, Issue:3

    Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa

2005
Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
    Alimentary pharmacology & therapeutics, 2005, Volume: 22 Suppl 2

    Topics: Adult; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metabolic Syndrome;

2005
[Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
    Der Internist, 2005, Volume: 46, Issue:12

    Topics: Diet Therapy; Exercise Therapy; Fatty Liver; Fatty Liver, Alcoholic; Humans; Liver Cirrhosis; Liver

2005
Review article: Drug therapy for non-alcoholic fatty liver disease.
    Alimentary pharmacology & therapeutics, 2006, Jan-15, Volume: 23, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic Acid; Betaine; Cholagogues and Chol

2006
Therapy of NAFLD: insulin sensitizing agents.
    Journal of clinical gastroenterology, 2006, Volume: 40 Suppl 1

    Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazolidinediones

2006
Treatment of nonalcoholic fatty liver disease.
    World journal of gastroenterology, 2006, Apr-14, Volume: 12, Issue:14

    Topics: Alanine Transaminase; Animals; Antioxidants; Body Mass Index; Fatty Liver; Humans; Hypolipidemic Age

2006
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:6

    Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglit

2006
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
    World journal of gastroenterology, 2006, Dec-28, Volume: 12, Issue:48

    Topics: Controlled Clinical Trials as Topic; Diet, Carbohydrate-Restricted; Fatty Liver; Humans; Hypoglycemi

2006
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Humans; Hypoglycemic Agents; Insulin

2007
Treatment of fibrosis in nonalcoholic fatty liver disease.
    Current gastroenterology reports, 2007, Volume: 9, Issue:1

    Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age

2007
[Pathogenetic treatment of non-alcoholic steatohepatitis: arguments, efficacy, safety].
    Terapevticheskii arkhiv, 2007, Volume: 79, Issue:8

    Topics: Exercise Therapy; Fatty Acids; Fatty Liver; Humans; Hypoglycemic Agents; Immunologic Factors; Metfor

2007
Use of insulin sensitizers in NASH.
    Endocrinology and metabolism clinics of North America, 2007, Volume: 36, Issue:4

    Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform

2007
Metformin beyond diabetes: new life for an old drug.
    Current diabetes reviews, 2006, Volume: 2, Issue:3

    Topics: Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglyc

2006

Trials

36 trials available for metformin and Fatty Liver

ArticleYear
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
    Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:7

    Topics: Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV In

2023
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
    Scientific reports, 2021, 03-29, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1

2021
Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation.
    Hormone research in paediatrics, 2018, Volume: 89, Issue:2

    Topics: Adiposity; Fatty Liver; Female; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Life Style; Metfor

2018
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:9

    Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2

2013
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
    Arquivos brasileiros de endocrinologia e metabologia, 2013, Volume: 57, Issue:9

    Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Blood Glucose; Body Mass Index; Body Weight; C-React

2013
Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:7

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Carnitine; DNA

2014
Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases.
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2014, Volume: 36, Issue:3

    Topics: Adiponectin; Adult; Aged; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Male; Metformin; M

2014
Effect of vildagliptin on hepatic steatosis.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:4

    Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration

2015
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
    Diabetes care, 2015, Volume: 38, Issue:7

    Topics: Adipose Tissue; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liv

2015
High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial.
    Diabetologia, 2016, Volume: 59, Issue:1

    Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Diet; Exercise; E

2016
Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Clinical therapeutics, 2008, Volume: 30, Issue:6

    Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Biopsy; Body Mass Index; Child; Fatty

2008
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Pediatric diabetes, 2009, Volume: 10, Issue:1

    Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child;

2009
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Pediatric diabetes, 2009, Volume: 10, Issue:1

    Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child;

2009
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Pediatric diabetes, 2009, Volume: 10, Issue:1

    Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child;

2009
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Pediatric diabetes, 2009, Volume: 10, Issue:1

    Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child;

2009
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
    Acta diabetologica, 2009, Volume: 46, Issue:2

    Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Fatty Liver; Female; Glycated Hemoglobi

2009
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2009, Volume: 29, Issue:2

    Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged

2009
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2009, Volume: 29, Issue:2

    Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged

2009
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2009, Volume: 29, Issue:2

    Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged

2009
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2009, Volume: 29, Issue:2

    Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged

2009
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
    Gastroenterology, 2008, Volume: 135, Issue:6

    Topics: Adolescent; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Child; Drug The

2008
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:1

    Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Fem

2010
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
    Contemporary clinical trials, 2010, Volume: 31, Issue:1

    Topics: Adolescent; Alanine Transaminase; Child; Double-Blind Method; Fatty Liver; Female; Humans; Hypoglyce

2010
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
    Scandinavian journal of gastroenterology, 2009, Volume: 44, Issue:7

    Topics: Administration, Oral; Adult; Biopsy; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fatty L

2009
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.
    International journal of obesity (2005), 2010, Volume: 34, Issue:8

    Topics: Adult; Body Mass Index; Diet; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Non

2010
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
    Obesity (Silver Spring, Md.), 2010, Volume: 18, Issue:9

    Topics: Adult; Alanine Transaminase; Biomarkers; Diabetes Mellitus; Fatty Liver; Female; Glucose Intolerance

2010
Metformin: a therapeutic option for treating nonalcoholic fatty liver disease.
    Digestive diseases and sciences, 2010, Volume: 55, Issue:7

    Topics: Diet; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Female; Follow-Up

2010
Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:9

    Topics: Adult; Aged; Arteries; Blood Flow Velocity; Blood Glucose; Fatty Liver; Female; Humans; Hypoglycemic

2011
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
    JAMA, 2011, Apr-27, Volume: 305, Issue:16

    Topics: Adolescent; Alanine Transaminase; Antioxidants; Child; Double-Blind Method; Fatty Liver; Female; Hum

2011
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination;

2011
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:1

    Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Fema

2012
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
    Diabetologia, 2011, Volume: 54, Issue:12

    Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy,

2011
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
    European journal of endocrinology, 2012, Volume: 166, Issue:3

    Topics: Adult; alpha-2-HS-Glycoprotein; Biomarkers; Cross-Sectional Studies; Dose-Response Relationship, Dru

2012
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?
    Cardiovascular diabetology, 2012, Jun-07, Volume: 11

    Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; Down-Regulation; Fatty Liver; Female; Hemodynam

2012
Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients.
    Diabetes care, 2012, Volume: 35, Issue:7

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Exercise; Fats; Fatty Acids, Monounsaturated; Fatty Liver; F

2012
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.
    Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2012, Volume: 60, Issue:7

    Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Fema

2012
Metformin superior to low‑fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis.
    Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122 Suppl 1

    Topics: Adult; Diet, Fat-Restricted; Fatty Liver; Female; Humans; Male; Metformin; Middle Aged; Non-alcoholi

2012
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:119

    Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases;

2012
Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:6

    Topics: Adult; Alanine Transaminase; Blood Flow Velocity; Diet; Fatty Liver; Female; Hemodynamics; Humans; H

2004
A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2005, Apr-01, Volume: 21, Issue:7

    Topics: Adolescent; Blood Glucose; Child; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistan

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2005, Volume: 100, Issue:5

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2005
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2008, Volume: 28, Issue:2

    Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Diet Therapy; Exercise Therapy; Fatty Live

2008

Other Studies

88 other studies available for metformin and Fatty Liver

ArticleYear
Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
    Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22

    Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Alanine Transaminase; Animals; Barbiturates; Body Weight; Cho

2012
The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes.
    Communications biology, 2022, 08-17, Volume: 5, Issue:1

    Topics: Animals; COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Fatty Liver; Hepatocytes; Humans; Metfo

2022
Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice.
    Aging cell, 2022, Volume: 21, Issue:9

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty Liver; Hyperglycemia; Hyp

2022
Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.
    Diabetologia, 2022, Volume: 65, Issue:12

    Topics: Adult; Animals; Body Composition; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Hig

2022
Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism.
    Applied biochemistry and biotechnology, 2023, Volume: 195, Issue:8

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Glucagon-Like Peptide-1 Receptor; Humans; Hyp

2023
Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota.
    American journal of physiology. Endocrinology and metabolism, 2019, 12-01, Volume: 317, Issue:6

    Topics: Ampicillin; Animals; Anti-Bacterial Agents; Diet, High-Fat; Fatty Liver; Gastrointestinal Microbiome

2019
Metformin Attenuates Ischemia-reperfusion Injury of Fatty Liver in Rats Through Inhibition of the TLR4/NF-κB Axis
    Balkan medical journal, 2020, 06-01, Volume: 37, Issue:4

    Topics: Animals; Fatty Liver; Hypoglycemic Agents; Metformin; Protective Factors; Rats; Rats, Sprague-Dawley

2020
Combination of bis (α-furancarboxylato) oxovanadium (IV) and metformin improves hepatic steatosis through down-regulating inflammatory pathways in high-fat diet-induced obese C57BL/6J mice.
    Basic & clinical pharmacology & toxicology, 2021, Volume: 128, Issue:6

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diet,

2021
Suppressor of cytokine signalling-2 controls hepatic gluconeogenesis and hyperglycemia by modulating JAK2/STAT5 signalling pathway.
    Metabolism: clinical and experimental, 2021, Volume: 122

    Topics: Animals; Blood Glucose; Cell Line; Cell Line, Tumor; Cytokines; Diabetes Mellitus, Experimental; Dia

2021
Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice.
    Molecular medicine reports, 2017, Volume: 16, Issue:1

    Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Autophagy; Body Weight; Diet, High-Fat; Dise

2017
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
    European journal of clinical investigation, 2017, Volume: 47, Issue:11

    Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus

2017
Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice.
    Phytotherapy research : PTR, 2017, Volume: 31, Issue:11

    Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diet, High-Fat; Dietary Supple

2017
AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development.
    EBioMedicine, 2018, Volume: 28

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultu

2018
Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.
    British journal of pharmacology, 2018, Volume: 175, Issue:9

    Topics: AMP-Activated Protein Kinases; Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Casse

2018
Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.
    Scientific reports, 2018, 04-12, Volume: 8, Issue:1

    Topics: Acyltransferases; Administration, Oral; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Chemo

2018
The effect of high fat diet and metformin treatment on liver lipids accumulation and their impact on insulin action.
    Scientific reports, 2018, 05-08, Volume: 8, Issue:1

    Topics: Animals; Blood Glucose; Ceramides; Diet, High-Fat; Diglycerides; Fatty Liver; Humans; Insulin Resist

2018
Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model.
    Scientific reports, 2018, 09-11, Volume: 8, Issue:1

    Topics: Aging; Animals; Cell Line, Tumor; Disease Models, Animal; Fatty Liver; Genome-Wide Association Study

2018
Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
    Toxicology and applied pharmacology, 2019, 02-15, Volume: 365

    Topics: Adenosine Triphosphate; Animals; Anticarcinogenic Agents; Carcinoma, Hepatocellular; Cell Line, Tumo

2019
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    World journal of gastroenterology, 2013, Feb-28, Volume: 19, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Biopsy; Cause of Death; Chi-Square Distribution; Decision Support Te

2013
Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
    American journal of physiology. Endocrinology and metabolism, 2013, Oct-15, Volume: 305, Issue:8

    Topics: Adipose Tissue, White; Animals; Anticarcinogenic Agents; Carcinogenesis; Carcinoma, Hepatocellular;

2013
Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein.
    International journal of molecular medicine, 2014, Volume: 33, Issue:1

    Topics: Animals; Cell Differentiation; Down-Regulation; Fatty Liver; Hepatocytes; Lipid Metabolism; Liver; M

2014
Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.
    American journal of physiology. Endocrinology and metabolism, 2014, Volume: 306, Issue:3

    Topics: Animals; Combined Modality Therapy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatt

2014
Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose; Glucose Intol

2014
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jul-08, Volume: 111, Issue:27

    Topics: AMP-Activated Protein Kinases; Animals; Carrier Proteins; Fatty Liver; Hypoglycemic Agents; Metformi

2014
Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway.
    Autophagy, 2015, Volume: 11, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Blood Glucose; Body Weight; Caloric Restriction;

2015
OCT1 in hepatic steatosis and thiamine disposition.
    Cell cycle (Georgetown, Tex.), 2015, Volume: 14, Issue:3

    Topics: Animals; Energy Metabolism; Fatty Liver; Humans; Metformin; Mice; Models, Biological; Organic Cation

2015
Biocompatible polymeric nanocomplexes as an intracellular stimuli-sensitive prodrug for type-2 diabetes combination therapy.
    Biomaterials, 2015, Volume: 73

    Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Chitosan; Diabetes Mellitus, Type 2; Endocytosis

2015
A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N).
    European journal of internal medicine, 2016, Volume: 29

    Topics: Adult; Diabetes Mellitus; Exons; Fatty Liver; Female; Heterozygote; Humans; Insulin; Insulin Resista

2016
Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53.
    International journal of molecular sciences, 2016, Jan-16, Volume: 17, Issue:1

    Topics: Animals; Benzothiazoles; Caloric Restriction; Cell Survival; Diet; Endoplasmic Reticulum Stress; Fat

2016
Metformin administration induces hepatotoxic effects in paraoxonase-1-deficient mice.
    Chemico-biological interactions, 2016, Apr-05, Volume: 249

    Topics: Animals; Aryldialkylphosphatase; Fatty Liver; Inflammation; Lipid Peroxides; Liver; Male; Metformin;

2016
Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1.
    The Journal of biological chemistry, 2016, May-13, Volume: 291, Issue:20

    Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Experimental; Dietary Fats; Enzyme Activa

2016
Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21.
    Mediators of inflammation, 2016, Volume: 2016

    Topics: 3T3-L1 Cells; Adipose Tissue; Adiposity; Animals; Body Weight; CD4-Positive T-Lymphocytes; Diet, Hig

2016
Metformin increases hepatic leptin receptor and decreases steatosis in mice.
    The Journal of endocrinology, 2016, Volume: 230, Issue:2

    Topics: ADAM10 Protein; ADAM17 Protein; Aged; Amyloid Precursor Protein Secretases; Animals; Diabetes Mellit

2016
Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver.
    European journal of pharmacology, 2016, Oct-15, Volume: 789

    Topics: Adipocytes; Adipokines; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Blood Pressure; Body

2016
The Short-term Effects of Insulin, Metformin and Insulin-Metformin Combination on the Liver Morphology in High Fat Diet / Streptozotocin Induced Diabetic Albino Rats.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2016, Volume: 26, Issue:12

    Topics: Animals; Antibiotics, Antineoplastic; Diabetes Mellitus, Experimental; Diet, High-Fat; Fatty Liver;

2016
Role of salt inducible kinase 1 in high glucose-induced lipid accumulation in HepG2 cells and metformin intervention.
    Life sciences, 2017, Mar-15, Volume: 173

    Topics: Fatty Liver; Gene Expression Regulation, Enzymologic; Glucose; Hep G2 Cells; Humans; Lipogenesis; Me

2017
Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat.
    European journal of pharmacology, 2009, Feb-14, Volume: 604, Issue:1-3

    Topics: Animals; Antioxidants; Blotting, Western; Body Weight; Disease Models, Animal; Fatty Liver; Lipid Pe

2009
Treatment of non-alcoholic fatty liver disease in children: swim at your own risk.
    Pediatric diabetes, 2009, Volume: 10, Issue:1

    Topics: Adolescent; Child; Fatty Liver; Humans; Metformin; Obesity; Patient Education as Topic; Randomized C

2009
Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Alimentary pharmacology & therapeutics, 2009, Mar-01, Volume: 29, Issue:5

    Topics: Alanine Transaminase; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin

2009
Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:7

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Disease Models, Animal; Eating

2009
Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis.
    Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:3

    Topics: Blotting, Western; Cell Survival; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Fatty

2010
Evaluation of a focal lesion in the liver. answer to the clinical challenges and images in GI question: image 3: Focal fatty infiltration.
    Gastroenterology, 2010, Volume: 139, Issue:2

    Topics: Diabetes Mellitus; Diet, Reducing; Exercise Therapy; Fatty Liver; Female; Humans; Hypoglycemic Agent

2010
Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Fatty Liver; Humans; Hypoglycemic

2010
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
    Diabetes/metabolism research and reviews, 2011, Volume: 27, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complicat

2011
Insulin resistance and liver microcirculation in a rat model of early NAFLD.
    Journal of hepatology, 2011, Volume: 55, Issue:5

    Topics: Acetylcholine; Amidines; Animals; Benzylamines; Diet, High-Fat; Disease Models, Animal; Endothelium;

2011
[Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2011, Volume: 49, Issue:2

    Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Fatty Liver; Insulin Resistance; Lipid

2011
AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.
    Cell metabolism, 2011, Apr-06, Volume: 13, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Atherosclerosis; Benzopyrans; Dietary Fats; Disease Models,

2011
Should metformin be our antiglycemic agent of choice post-transplantation?
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2011, Volume: 11, Issue:7

    Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Cardiovascular Diseases; Diabetes Mellitus, Type

2011
Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way?
    Nature reviews. Gastroenterology & hepatology, 2011, Jul-12, Volume: 8, Issue:8

    Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Humans; Life Style; Metformin; Non-alcoholic F

2011
Targeting the renin-angiotensin system: potential beneficial effects of the angiotensin II receptor blockers in patients with nonalcoholic steatohepatitis.
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:6

    Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Thiazolidinediones

2011
Adiponectin levels in nonalcoholic fatty liver disease.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:12

    Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin

2011
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
    Hepatology (Baltimore, Md.), 2011, Volume: 54, Issue:5

    Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglita

2011
Current world literature.
    Current opinion in lipidology, 2011, Volume: 22, Issue:6

    Topics: Cardiotonic Agents; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; Fatty Acids, Omega-3;

2011
Medical therapy for nonalcoholic fatty liver disease in children and adolescents.
    Expert review of gastroenterology & hepatology, 2012, Volume: 6, Issue:1

    Topics: Adolescent; Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Non-alcoholic

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:6

    Topics: Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metformin; Non-alco

2012
Non-alcoholic fatty liver disease in children.
    Clinics and research in hepatology and gastroenterology, 2012, Volume: 36, Issue:3

    Topics: Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver; Metformin; Obesity; Piog

2012
Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function.
    Laboratory investigation; a journal of technical methods and pathology, 2012, Volume: 92, Issue:7

    Topics: Animals; Disease Models, Animal; Endotoxins; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Ag

2012
Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2011, Volume: 81, Issue:6

    Topics: Adiponectin; Adolescent; Cholesterol, LDL; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin

2011
Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin.
    Journal of proteomics, 2012, Dec-21, Volume: 77

    Topics: Animals; Apolipoproteins E; Disease Models, Animal; Fatty Liver; Hypoglycemic Agents; Metformin; Mic

2012
Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: Animals; Cluster Analysis; Disease Models, Animal; Fatty Liver; Gene Expression Profiling; Gene Expr

2012
TAp63 is a master transcriptional regulator of lipid and glucose metabolism.
    Cell metabolism, 2012, Oct-03, Volume: 16, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Energy Metabolism; Fatty Acids; Fatty Liver; Gluc

2012
Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Adenylate Kinase; AMP Deaminase; Animals; Carbon-Carbon Double Bond Isomerases; Enzyme Activation; F

2012
Phosphorylated forms of GNMT in mouse liver.
    Journal of proteomics, 2013, Jul-11, Volume: 87

    Topics: Animals; Apolipoproteins E; Fatty Liver; Hypoglycemic Agents; Metformin; Mitochondria, Liver; Mitoch

2013
Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:2

    Topics: Animals; Fatty Liver; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Obese

2003
Nonalcoholic steatohepatitis: role of leptin in pathogenesis and benefits of metformin in treatment.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:10

    Topics: Fatty Liver; Female; Follow-Up Studies; Humans; Leptin; Liver Function Tests; Male; Metformin; Risk

2003
[Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2005, Volume: 13, Issue:2

    Topics: Animals; Dietary Fats; Fatty Liver; Hypoglycemic Agents; Male; Metformin; Random Allocation; Rats; R

2005
[Drug therapy for nonalcoholic fatty liver disease].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2005, Volume: 13, Issue:2

    Topics: Antioxidants; Fatty Liver; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Quaternary

2005
The Diabetes Prevention Program and the metabolic syndrome.
    Annals of internal medicine, 2005, Oct-04, Volume: 143, Issue:7

    Topics: Combined Modality Therapy; Diet, Reducing; Exercise Therapy; Fatty Liver; Humans; Hypoglycemic Agent

2005
[Effects of metformin on fatty liver in insulin-resistant rats].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2005, Volume: 13, Issue:12

    Topics: Animals; Fatty Liver; Insulin Resistance; Male; Metformin; Random Allocation; Rats; Rats, Wistar

2005
Clinical Research Network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children.
    Journal of pediatric gastroenterology and nutrition, 2006, Volume: 42, Issue:2

    Topics: Adolescent; Antioxidants; Child; Clinical Trials as Topic; Data Collection; Fatty Liver; Female; Hum

2006
Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
    The American journal of gastroenterology, 2006, Volume: 101, Issue:6

    Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde

2006
[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
    Zhonghua yi xue za zhi, 2006, May-16, Volume: 86, Issue:18

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholesterol; Dietary Fats; Disease Model

2006
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
    World journal of gastroenterology, 2006, Jul-21, Volume: 12, Issue:27

    Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetim

2006
Incretin mimetics as a novel therapeutic option for hepatic steatosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2006, Volume: 26, Issue:8

    Topics: Diabetes Mellitus, Type 2; Exenatide; Fatty Liver; Humans; Hypoglycemic Agents; Male; Metformin; Mid

2006
Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity.
    The New England journal of medicine, 2006, Oct-12, Volume: 355, Issue:15

    Topics: Acanthosis Nigricans; Adolescent; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Liver; Female; G

2006
CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice.
    The Journal of biological chemistry, 2007, May-25, Volume: 282, Issue:21

    Topics: Adiposity; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Diabetes Mellitus; Energy Metabo

2007
The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease.
    Digestive diseases and sciences, 2007, Volume: 52, Issue:9

    Topics: Adult; Biopsy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Exercise Therapy; Fatty Liver

2007
Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome.
    Journal of pediatric endocrinology & metabolism : JPEM, 2007, Volume: 20, Issue:9

    Topics: Abnormalities, Multiple; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; H

2007
Metformin in polycystic ovary syndrome.
    The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17

    Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Sy

2008
Non-alcoholic steatohepatitis.
    Lancet (London, England), 1999, Oct-09, Volume: 354, Issue:9186

    Topics: Chromans; Contraindications; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic

1999
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
    Nature medicine, 2000, Volume: 6, Issue:9

    Topics: Adenosine Triphosphate; Adipose Tissue; Animals; Body Weight; Energy Intake; Energy Metabolism; Fatt

2000
Metformin in non-alcoholic steatohepatitis.
    Lancet (London, England), 2001, Sep-15, Volume: 358, Issue:9285

    Topics: Adult; Alanine Transaminase; Body Mass Index; Body Weight; Fatty Liver; Female; Humans; Hypoglycemic

2001
Metformin in non-alcoholic steatohepatitis.
    Lancet (London, England), 2002, Jan-26, Volume: 359, Issue:9303

    Topics: Acidosis, Lactic; Fatty Liver; Follow-Up Studies; Humans; Liver Function Tests; Metformin; Risk Fact

2002
[Fatty liver and raised gamma-GT: it can happen to abstainers, too].
    MMW Fortschritte der Medizin, 2002, Feb-14, Volume: 144, Issue:7

    Topics: Cholagogues and Choleretics; Clinical Enzyme Tests; Diabetes Complications; Diagnosis, Differential;

2002
Comparative effects of metformin and phenformin on the progression and regression of cholesterol induced athreosclerosis in rabbits.
    Paroi arterielle, 1979, Volume: 5, Issue:4

    Topics: Animals; Arteriosclerosis; Cholesterol, Dietary; Fatty Liver; Lipid Metabolism; Liver; Male; Metform

1979
[Inhibitory effects of the certain antidiabetic biguanides upon the intestinal absorption of lipids].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles, 1972, Oct-16, Volume: 275, Issue:16

    Topics: Animals; Cholesterol; Diet, Atherogenic; Dietary Proteins; Fatty Liver; Feces; Glycerides; Intestina

1972
The effects of metformin on lipid-induced atherosclerosis.
    Advances in metabolic disorders, 1973, Volume: 2

    Topics: Animals; Arteries; Arteriosclerosis; Blood Glucose; Cholesterol; Diet, Atherogenic; Fatty Acids, Non

1973
[On the clinical use of biguanides].
    Arzneimittel-Forschung, 1969, Volume: 19, Issue:4

    Topics: Aged; Biguanides; Blood Glucose; Body Weight; Cholesterol; Depression, Chemical; Diabetes Mellitus;

1969